Pleo Oku
FDA Label NDC 60681-2402

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Sanum-kehlbeck Gmbh & Co. Kg for the product Pleo Oku (NDC 60681-2402). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding otc - purpose, indications, ingredients, tamper evident, acute, chronic, warning, otc - keep out of reach of children, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Otc - Purpose

Homeopathic Antidiarrheal Medicine

Indications

For temporary relief of acute diarrhea.

Ingredients

One tablet contains 250 mg Okoubaka aubrevillei 2X in a base of lactose, potato starch, magnesium stearate.

Tamper Evident

Do not use this product if imprinted inner blister pack is broken.

Acute

1 tablet every half to full hour up to a max. of 12 times daily.

Chronic

2 tablets daily.

Warning

lf symptoms persist more than a few days, contact a licensed practitioner. As with any drug, if you are pregnant or nursing a baby, seek the advice of a health care professional before using this product.

Otc - Keep Out Of Reach Of Children

Keep this and all other medications out of the reach of children. In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately.

Other

Rev. 04/2012

Manufactured by:
Sanum-Kehlbeck
GmbH & Co. KG
Hoya, Germany

Distributed by:
SANUM USA Corp.
1465 Slater Road
Ferndale, WA 98248

Principal Display Panel - 80 Tablet Carton

Pleo® Oku
TABLETS 2X

Homeopathic
Antidiarrheal
Medicine

The original
SANUM®

brand remedies

Indications: For temporary relief of
acute diarrhea.

80 TABLETS

Principal Display Panel (80 Tablet Carton)

Principal Display Panel (80 Tablet Carton)

* Please review the disclaimer below.